ES2538282A1 - Im-9r drug-resistant tumor cell line and its use in the search for new anti-tumor treatments (Machine-translation by Google Translate, not legally binding) - Google Patents

Im-9r drug-resistant tumor cell line and its use in the search for new anti-tumor treatments (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2538282A1
ES2538282A1 ES201301196A ES201301196A ES2538282A1 ES 2538282 A1 ES2538282 A1 ES 2538282A1 ES 201301196 A ES201301196 A ES 201301196A ES 201301196 A ES201301196 A ES 201301196A ES 2538282 A1 ES2538282 A1 ES 2538282A1
Authority
ES
Spain
Prior art keywords
drug
cell line
mdr
resistant
translation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201301196A
Other languages
Spanish (es)
Other versions
ES2538282B1 (en
Inventor
Elena MARTÍN-OROZCO SANTIAGO
David CEREZO FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Murcia
Original Assignee
Universidad de Murcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Murcia filed Critical Universidad de Murcia
Priority to ES201301196A priority Critical patent/ES2538282B1/en
Publication of ES2538282A1 publication Critical patent/ES2538282A1/en
Application granted granted Critical
Publication of ES2538282B1 publication Critical patent/ES2538282B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Drug-resistant tumor cell line im-9r and its use in the search for new anti-tumor treatments. Im-9r is a drug-resistant cell line that expresses the mdr-1 protein and has drug extruder capacity. In addition, it presents collateral sensitivity to hypothermia and a bcl-2 protein expression profile associated with the mdr phenotype. This line will allow the development of new therapies aimed at the treatment of chemo-resistant tumors and will enable the design of predictive tests of response to drugs that allow the analysis of new molecules and their combinations for the personalized treatment of patients with neoplastic processes. Additionally, the im-9r line will allow identifying intracellular signaling molecules involved in the process of collateral sensitivity to hypothermia, which could constitute new therapeutic targets in the treatment of mdr tumors. Finally, said cell line will enable the identification of inhibitors of mdr-1 and bcl-2 proteins, such as mcl-1. (Machine-translation by Google Translate, not legally binding)

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

Claims (1)

imagen1image 1
ES201301196A 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments Active ES2538282B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201301196A ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201301196A ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Publications (2)

Publication Number Publication Date
ES2538282A1 true ES2538282A1 (en) 2015-06-18
ES2538282B1 ES2538282B1 (en) 2016-05-09

Family

ID=53379961

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201301196A Active ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Country Status (1)

Country Link
ES (1) ES2538282B1 (en)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRÜNING et al. "The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization" BioMed Central Ltd. Vol. 9, doi:10.1186/1476-4598-9-19; todo el documento. *
CAMPBELL KIRSTEEN J et al. "Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance" Blood OCT 28 2010 00/10/2010 VOL: 116 No: 17 Pags: 3197-3207 ISSN 0006-4971(print) ISSN 1528-0020(electronic) Doi: doi:10.1182/blood-2010-04-281071; todo el documento. *
CASTRO-GALACHE MARIA D et al. "Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors" International Journal of Cancer 1 May, 2003 01/05/2003 VOL: 104 No: 5 Pags: 579-586 ISSN 0020-7136; todo el documento. *
CEREZO DAVID et al. "Acquisition of MDR phenotype by leukemic cells is associated with increased caspase-3 activity and a collateral sensitivity to cold stress" Journal of Cellular Biochemistry APR 2012 00/04/2012 VOL: 113 No: 4 Pags: 1416-1425 ISSN 0730-2312(print) ISSN 1097-4644(electronic) Doi: doi:10.1002/jcb.24016; todo el documento. *
DAVID CEREZO FERNANDEZ "Estudio del proceso de sensibilidad colateral en células laucémicas murinas y humanas con fenotipo de resistencia a múltipoles fármacos (MDR)" Tesis Doctoral. Departamento de Bioquímica y Biología Molecular B e Inmunología. Universidad de Murcia. (partes no sujetas a procesos de protección o transferencia de tecnología o de conocimiento, por no estar publicados en la fecha de la solicitud). Recuperado en línea [recuperado el 03/12/2014] Recuperado de Internet: <URL: http://digitum.um.es/xmlui/bitstream/10201/36091/6/Tesis%20%20David%20Cerezo%20Fern%C3%A1ndez%20(incluye%20contenidos%20inhibidos).pdf> *
HALL M D et al. "Is resistance useless? Multidrug resistance and collateral sensitivity" TRENDS IN PHARMACOLOGICAL SCIENCES, 20091001 ELSEVIER, HAYWARTH, GB 01/10/2009 VOL: 30 No: 10 Pags: 546 - 556 ISSN 0165-6147 Doi: doi:10.1016/j.tips.2009.07.003; todo el documento. *

Also Published As

Publication number Publication date
ES2538282B1 (en) 2016-05-09

Similar Documents

Publication Publication Date Title
Chang et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
Kang et al. HMGB1 in health and disease
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
BR112016030462A2 (en) binding molecules, one or more isolated polynucleotides, one or more vectors, host cell, method of producing a binding molecule, pharmaceutical composition, use of the binding molecule, method of treating disease and inducing target cell lysis
Sui et al. Interleukin‑17 promotes the development of cisplatin resistance in colorectal cancer
AR115389A1 (en) CD73 ANTAGONIST ANTIBODY
AR092818A1 (en) HUMANIZED TAU ANTIBODY
EA201892635A1 (en) IMMUNODULATORS FOR PET VISUALIZATION
BR112016018205A8 (en) methods of treating alzheimer&#39;s disease, patient selection, patient identification, prediction, therapeutic efficacy optimization, kit, agent use and in vitro agent use
BR112018067713A2 (en) antifalpha antibodies and functional fragments thereof
ES2540255A1 (en) Method of isolation of apoptotic bodies (Machine-translation by Google Translate, not legally binding)
AR104484A1 (en) ANTI-PSMA ANTIBODIES AS THERAPEUTIC AGENTS
Yang et al. Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer
ES2538282A1 (en) Im-9r drug-resistant tumor cell line and its use in the search for new anti-tumor treatments (Machine-translation by Google Translate, not legally binding)
BR112017006569A2 (en) composition, method for producing a composition, method for detecting antibodies, use of a composition and antibody detection reagent kit
Davids et al. Mitochondrial apoptotic priming is associated with clinical response to the Bcl-2 antagonist ABT-199 in chronic lymphocytic leukemia
Du et al. Brain death induces the alteration of liver protein expression profiles in rabbits
JP2015517500A5 (en)
Stavrovskaya et al. Secreted protein YB-1 and its prognostic significance
Adams et al. Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies.
ES2517190A1 (en) Canine mammary inflammatory carcinoma cell line (Machine-translation by Google Translate, not legally binding)
Pierceall et al. Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia
ES2464440B2 (en) Spectroscopic method for the determination of proteins in complex media.
ES2560902A2 (en) Method for determining degree of modified potency of a medicament
RU2013122192A (en) METHOD FOR PREDICTING THE PRESENCE OF PRIMARY-MULTIPLE SYNCHRONOUS COLUMN CANCER

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2538282

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160509